Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR) on Continued Positive Script Trends and Aggressive Strategy
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.
Canaccord analyst, George Farmer, said, "OPTR reported 2011 DIFICID gross sales of $24.4M, a total of $12.1M in Q3/11 (includes $5.1M to fully-stock inventory) and $12.2M in Q4/11, with strong Q4 m/m growth of ~11%. End of Q4/11 inventory decreased $1.1M, resulting in Q4/11 ex-wholesaler sales of $13.3M, a 90% increase compared to Q3/11 ex-wholesaler sales of $7M. This is reflected in an 87% increase between Q3 and Q4 of wholesale shipments from 2505 to 4675 treatments. DIFICID shipments to wholesalers in Q4/11 grew at an 11.3% compounded monthly growth rate. We now model for the Euro 50M Astellas milestone payment in Q2/12."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.65 yesterday.
Canaccord analyst, George Farmer, said, "OPTR reported 2011 DIFICID gross sales of $24.4M, a total of $12.1M in Q3/11 (includes $5.1M to fully-stock inventory) and $12.2M in Q4/11, with strong Q4 m/m growth of ~11%. End of Q4/11 inventory decreased $1.1M, resulting in Q4/11 ex-wholesaler sales of $13.3M, a 90% increase compared to Q3/11 ex-wholesaler sales of $7M. This is reflected in an 87% increase between Q3 and Q4 of wholesale shipments from 2505 to 4675 treatments. DIFICID shipments to wholesalers in Q4/11 grew at an 11.3% compounded monthly growth rate. We now model for the Euro 50M Astellas milestone payment in Q2/12."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- UBS Downgrades Converge ICT Solutions Inc (CNVRG:PM) to Neutral
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
